comorbidity index

Role of Patient’s Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

LYMPHOID TUMORS , ,

VV Strugov1, EA Stadnik1,2, YuV Virts1, TO Silina1, AYu Zaritskii1,2

1 V.A. Almazov Federal North-West Medical Research Centre, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341

2 Academician I.P. Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022

For correspondence: Vladimir Vladimirovich Strugov, scientific worker, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341; Tel.: +7(906)277-86-64; e-mail: strugov@almazovcentre.ru

For citation: Strugov VV, Stadnik EA, Virts YuV, et al. Role of Patient’s Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia. Clinical oncohematology. 2016;9(2):162–75 (In Russ).

DOI: 10.21320/2500-2139-2016-9-2-162-175

ABSTRACT

Background & Aims. New schemes of the antitumor therapy of CLL resulted in improvement of survival of relatively young patients. However, the therapy outcomes of elderly patients are still unsatisfactory. Erroneous overestimation of expected toxicity of standard therapeutic regimens in some elderly patients may play a certain role, thus leading to prescription of less effective regimens. Therefore, the urgent problem is to find objective criteria for risk stratification in CLL. The aim of the study is to evaluate the prognostic significance of patient’s age and the CIRS-G index in elderly patients treated with fludarabine-containing regimens in first line treatment outside clinical trials.

Methods. A retrospective analysis of 90 elderly CLL patients, treated with standard FC and FCR regimens in the clinic of internal medicine of the First St. Petersburg State Medical University from 2001 till 2011. The age median was 59 years (range from 43 to 78 years). The comorbidity index was determined for each patient using the CIRS-G score.

Results. The overall response rate did not significantly differ between FC and FCR groups and was equal to 81.6 % and 93.4 %, respectively (p = 0.109). Complete remissions were achieved in 72.3 % of FCR group patients and only in 46.5 % of FC group patients (p = 0.018). The retrospective analysis of treatment tolerability in primary elderly patients with different CIRS-G scores in the routine clinical practice demonstrated that the index has no independent prognostic significance. Among all CIRS-G components (14 organs and systems), only renal and hepatic diseases demonstrated significant correlation with the overall survival rate (p < 0.001 and p = 0.028, respectively).

Conclusion. The creatinine clearance value in the beginning of treatment is the most important predictor of FC and FCR regimen efficacy in elderly patients. The use of the comorbidity index with a 6-score threshold as a contraindication for fludarabine-containing regimens proved to be unjustified.

Keywords: chronic lymphocytic leukemia, CLL, comorbidity index, CIRS-G, FCR.

Received: January 15, 2016

Accepted: February 3, 2016.

Read in PDF (RUS) pdficon

REFERENCES

  1. Del Giudice I, Mauro FR, Foa R. Chronic lymphocytic leukemia in less fit patients: “slow-go”. Leuk Lymphoma. 2011;52(12):2207–16. doi: 10.3109/10428194.2011.606386.
  2. Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10(9):1389–94. doi: 10.1586/era.10.127.
  3. Ожидаемая продолжительность предстоящей жизни по Российской Федерации [электронный документ]. Доступно по: http://www.gks.ru/free_doc/new_site/population/generation/dem2.xlsx. Ссылка активна на 15.08.2015.
    [Ozhidaemaya prodolzhitel’nost’ predstoyashchei zhizni po Rossiiskoi Federatsii. (Life expectancy in the Russian Federation.) [Internet] Available from: http://www.gks.ru/free_doc/new_site/population/generation/dem2.xlsx. (accessed 15.08.2015) (In Russ)]
  4. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975–80. doi: 10.1182/blood-2008-02-140582.
  5. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet. 2010;376(9747):1164–74. doi: 10.1016/S0140-6736(10)61381-5.
  6. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044–50. doi: 10.1182/blood-2009-04-214346.
  7. Merli F, Mammi C, Ilariucci F. Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future. Curr Oncol Rep. 2015;17(7):31. doi: 10.1007/s11912-015-0454-0.
  8. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. doi: 10.1182/blood-2007-06-093906.
  9. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80(7):1273–83. doi: 10.1002/(sici)1097-0142(19971001)80:7<1273::aid-cncr13>3.0.co;2-4.
  10. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56. doi: 10.1080/10428190701724785.
  11. Molica S, Brugiatelli M, Morabito F, et al. Treatment of elderly patients with chronic lymphocytic leukemia: an unmet clinical need. Expert Rev Hematol. 2013;6(4):441–9. doi: 10.1586/17474086.2013.814845.
  12. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095–100. doi: 10.3324/haematol.2013.096792.
  13. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(2):171–8. doi: 10.1080/10428190802688517.
  14. Miller M, Towers A. A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). May 1991. [Internet] Available from: http://www.anq.ch/fileadmin/redaktion/deutsch/20121211_CIRSG_Manual_E.pdf. (accessed 12.04.2016).
  15. Stilgenbauer S, Montillo M, Tadeusz R, et al. Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. Blood. 2013;122(21): Abstract 4156.
  16. Никитин Е.А., Халлек М., Байков В.В. и др. Российские клинические рекомендации по диагностике и лечению хронического лимфолейкоза (версия 2012 г.). Клиническая онкогематология. 2013;6(1):99–109.
    [Nikitin EA, Khallek M, Baykov VV, et al. Russian clinical guidelines for diagnosis and treatment of chronic lymphocytic leukemia (version 2012). Klinicheskaya onkogematologiya. 2013;6(1):99–109. (In Russ)]
  17. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494–502. doi: 10.1200/jco.20.2.494.
  18. Bonanad S, De la Rubia J, Gironella M, et al. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. J Geriatr Oncol. 2015;6(5):353–61. doi 10.1016/j.jgo.2015.03.003.
  19. Стругов В.В., Стадник Е.А., Вирц Ю.В., Зарицкий А.Ю. Ретроспективное исследование результатов применения режимов FC/FCR в первой линии терапии хронического лимфолейкоза. Трансляционная медицина. 2012;6(17):104–15.
    [Strugov VV, Stadnik EA, Virts YuV, Zaritskii AYu. Retrospective studies of outcomes of FC/FCR regimens in first-line therapy if chronic lymphocytic leukemia. Translyatsionnaya meditsina. 2012;6(17):104–15. (In Russ)]
  20. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56(10):1926–31. doi: 10.1111/j.1532-5415.2008.01935.x.
  21. Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015;33(19):2212–20. doi: 10.1200/JCO.2015.61.3745.
  22. Стадник Е.А., Никитин Е.А., Бидерман Б.В. и др. Ретроспективное сравнение эффективности и токсичности режимов лечения FC и FCR у первичных больных В-клеточным хроническим лимфолейкозом. Онкогематология. 2008;1–2:39–46.
    [Stadnik EA, Nikitin EA, Biderman BV, et al. Comparison of efficacy and toxicity of FC and FCR regimens in the treatment of primary B-cell chronic lymphocytic leukemia: a retrospective study. Onkogematologiya. 2008;1–2:39–46. (In Russ)]
  23. Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–85. doi: 10.1182/blood-2005-12-051458.
  24. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62. doi: 10.1182/blood-2014-02-556399.
  25. Baumann T, Delgado J, Santacruz R, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014;99(10):1599–604. doi: 10.3324/haematol.2014.107326.
  26. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12. doi: 10.1053/ajkd.2003.50007.
  27. Пигарева Ю.А., Авдошина С.В., Дмитрова Т.Б. и др. Распространенность хронической болезни почек среди пациентов терапевтического стационара. Клиническая нефрология. 2012;3:4–9.
    [Pigareva YuA, Avdoshina SV, Dmitrova TB, et al. Prevalence of chronic kidney disease in patients of clinic of internal diseases. Klinicheskaya nefrologiya. 2012;3:4–9. (In Russ)]
  28. Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002;50(1):37–45. doi: 10.1007/s00280-002-0443-5.
  29. Michallet AS, Cazin B, Bouvet E, et al. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. J Geriatr Oncol. 2013;4(2):141–7. doi: 10.1016/j.jgo.2013.01.002.
  30. Kolibaba KS, Sterchele JA, Joshi AD, et al. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013;4(3):157–71. doi: 10.1177/2040620713478629.
  31. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 study). Blood. 2014;124(21): Abstract 19.
  32. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi: 10.1056/NEJMoa1313984.
  33. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58. doi: 10.1016/S1470-2045(13)70513-8.
  34. Zelenetz AD, Gordon LI, Wierda WG, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015;13(3):326–62.